- Home
- VINP vs HUMA Comparison
VINP vs HUMA Comparison
Compare VINP & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | HUMA |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 165.7M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VINP | HUMA |
|---|---|---|
| Price | $10.65 | $0.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $14.02 | $1.85 |
| AVG Volume (30 Days) | 41.4K | ★ 2.9M |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | $17.76 | $72.32 |
| Revenue Next Year | $13.10 | $518.79 |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $0.50 |
| 52 Week High | $13.61 | $1.97 |
Technical Indicators
Market Signals| Indicator | VINP | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 73.75 | 31.45 |
| Support Level | $9.36 | N/A |
| Resistance Level | $10.88 | $0.61 |
| Average True Range (ATR) | 0.30 | 0.03 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 97.53 | 12.55 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.